Five Prime Therapeutics, Inc. Deferred Revenue Recognized
Five Prime Therapeutics, Inc. reported Deferred Revenue Recognized of $4.52 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-22.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2021-03-22
- Five Prime Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2020-03-31 was $1.92M, a 23.56% decline year-over-year.
- Five Prime Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2019-03-31 was $2.52M, a 24.16% decline year-over-year.
- Five Prime Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2018-03-31 was $3.32M.
- Five Prime Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2020 was $4.52M, a 24.42% decline from fiscal 2019.
- Five Prime Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2019 was $5.97M, a 51.10% decline from fiscal 2018.
- Five Prime Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2018 was $12.22M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2020-12-31 | $4.52M 10-K · filed 2021-03-22 | |||
| 2020-09-30 | $4.22M 10-Q · filed 2020-11-03 | |||
| 2020-06-30 | $3.26M 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $1.92M 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $5.97M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $4.54M 10-Q · filed 2019-11-06 | |||
| 2019-06-30 | $3.19M 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $2.52M 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | $12.22M 10-K · filed 2019-02-26 | |||
| 2018-09-30 | $9.89M 10-Q · filed 2018-11-06 | |||
| 2018-06-30 | $6.98M 10-Q · filed 2018-08-08 | |||
| 2018-03-31 | $3.32M 10-Q · filed 2018-05-08 |